BioSpace News Archive

HanAll Biopharma achieved 18.4 percent revenue growth in the first quarter compared to the same period last year, recording a revenue of 34.1 billion Korean Won, driven by continued strong sales across key products.

Oncolytics Biotech ® Inc. today announced that it will host a conference call and webcast on Thursday, May 9, 2024.

Veru Inc. announced that it has enrolled the first patients in its Phase 2b clinical trial of enobosarm, an oral selective androgen receptor modulator, to avoid muscle loss and to augment fat loss when combined with semaglutide, a Glucagon-like peptide-1 receptor agonist drug, for potentially higher quality weight loss.

Wave Life Sciences Ltd. announced the approval of its first clinical trial application for its RestorAATion-2 clinical trial of WVE-006, the company’s first-in-class RNA editing oligonucleotide, which is being developed for the treatment of alpha-1 antitrypsin deficiency.

NRx Pharmaceuticals, Inc., a clinical stage pharmaceutical company today that its Breakthrough Therapy designated investigational drug NRX-101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduction in symptoms of akathisia – a side effect of antidepressants that is closely linked to suicide and considered a medical emergency.

SonoThera today announced that it will present four abstracts at the 27th annual meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place in Baltimore, Maryland, May 7-11, 2024.

Tharimmune, Inc. announced that management will be participating in two investor conferences in May.

Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”) today announced that it will present new data from its ongoing real-world registry study of Revita for T2D at the upcoming German Diabetes Association (DDG) Annual Meeting taking place May 8-11, 2024, in Berlin, Germany.

ARS Pharmaceuticals, Inc. announced that it has submitted its Day 180 response to the Committee for Medicinal Products for Human Use of the European Medicines Agency for its Marketing Authorization Application for neffy®, an investigational new drug to be indicated for the treatment of Type I allergic reactions including anaphylaxis.

CERo Therapeutics Holdings, Inc., announces it is presenting preclinical data on its lead product candidate CER-1236 at the Stanford Drug Discovery Symposium, which is being held April 29-30, 2024 in Palo Alto, Calif.